BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Deloitte
Queensland Health
Boehringer Ingelheim
Farmers Insurance
Argus Health
Moodys
Merck
Julphar
Cantor Fitzgerald

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020822

« Back to Dashboard

NDA 020822 describes CELEXA, which is a drug marketed by Forest Labs and is included in two NDAs. It is available from three suppliers. Additional details are available on the CELEXA profile page.

The generic ingredient in CELEXA is citalopram hydrobromide. There are fifty-six drug master file entries for this compound. Seventy suppliers are listed for this compound. Additional details are available on the citalopram hydrobromide profile page.
Summary for 020822
Tradename:CELEXA
Applicant:Forest Labs
Ingredient:citalopram hydrobromide
Patents:0
Therapeutic Class:Antidepressants
Formulation / Manufacturing:see details
Pharmacology for NDA: 020822
Mechanism of ActionSerotonin Uptake Inhibitors
Medical Subject Heading (MeSH) Categories for 020822
Suppliers and Packaging for NDA: 020822
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CELEXA citalopram hydrobromide TABLET;ORAL 020822 NDA Allergan USA, Inc. 0456-4010 0456-4010-01 100 TABLET, FILM COATED in 1 BOTTLE (0456-4010-01)
CELEXA citalopram hydrobromide TABLET;ORAL 020822 NDA Allergan USA, Inc. 0456-4020 0456-4020-63 10 BLISTER PACK in 1 BOX, UNIT-DOSE (0456-4020-63) > 10 TABLET, FILM COATED in 1 BLISTER PACK (0456-4020-11)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:Apr 27, 2000TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 20MG BASE
Approval Date:Jul 17, 1998TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 40MG BASE
Approval Date:Jul 17, 1998TE:ABRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Queensland Health
Chinese Patent Office
Chubb
Johnson and Johnson
Moodys
McKesson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot